VCP Scanner
Stock Screener
Filter stocks with fundamental & technical criteria
Market Themes
Curated industry baskets & thematic leaders
Earnings Hub
Calendar, EPS surprise stats & earnings transcripts
Market News
Real-time market intelligence & AI overviews
Insider Buying
SEC Form 4 corporate insider purchases
LearnAll lessons
Candlestick Patterns44 candles, each on two real charts
Pattern GuidesThe playbooks' setups on real breakouts
GlossaryInvesting terms in plain English
MinerviniVCP SetupsTrend Template
O'NeilCup with HandleFlat BaseDouble BottomCANSLIM Leaders
QullamaggieHigh Tight FlagsFlag BreakoutsEpisodic PivotsMomentum Leaders
KellWedge PopEMA Crossback
LivermorePivotal Points
PatternsFalling Wedge & ChannelBase Breakouts
View All Playbooks...
BreakoutsScanner
FAANG & Tech
AAPL vs MSFTNVDA vs AMDGOOGL vs META
Cloud & Cyber
CRM vs NOWCRWD vs PANWSNOW vs DDOG
Consumer & Auto
TSLA vs FAMZN vs WMTNFLX vs DIS
Finance & Crypto
JPM vs BACV vs MACOIN vs MSTR
Index & ETFs
SPY vs QQQVTI vs VOOSPY vs IWM
Compare Any Stocks...
DCF ValuationCalculate intrinsic value of US stocks
Market ValuationBuffett indicator, CAPE & macro gauges
Total ReturnSee dividends + price return history
DCA CalculatorSimulate recurring buys & compounding
VisualizeInteractive multi-year financial charts
Watchlist
BreakoutsScanner
WatchlistPricing
Ctrl K
Pricing
LSTA
← Back to Screener
VCP ScannerFree US Stock Screener & Financial Analysis

Find stocks. Analyze deeply. Research with clarity.

Data updated daily

Product

  • Screener
  • Scanner
  • Themes
  • Valuation
  • Total Return
  • DCA Calculator
  • Pricing
  • News
  • Earnings

Resources

  • Market Valuation
  • Compare
  • Insider Activity
  • Methodology
  • How It Works
  • Glossary
  • Learn

Get Ideas

Get weekly market insights — free

© 2026 VCP Scanner
AboutPrivacyTermsRefund Policy
Not financial advice. Do your own research.
ScreenerBreakoutsScannerWatchlist
LSTALisata Therapeutics, Inc.
$1.04$9M
Overview & Tools
OverviewChart Terminal ↗Visualize
Valuation & Forecasts
Valuation ModelsEstimatesDCF Model
Price & Analyst Data
Analyst TargetsPrice History
Financial Statements
Income StatementBalance SheetCash FlowRatios & Margins
Performance
P/E HistoryRevenue HistoryEarnings HistoryDividend HistoryTotal Return
Discovery & Screens
Live BreakoutsStock ScreenerOwnership
LSTA logo

Lisata Therapeutics, Inc.

LSTA
NASDAQ · Oncology Biotech
$1.04
At close - Nov 17, 4:00 PM EST - USD
Market Cap$9M
P/E-0.6x
52W High$5.07
Volume246.91K
OverviewTerminalAnalysisFinancialsValuationEarningsBreakoutsOwnership
VCP Research Verdict2026Q1

Persistent Cash Burn Threatens Clinical Development Runway

Lisata Therapeutics remains a high-risk, pre-revenue entity whose valuation is entirely dependent on the success of its CendR platform, yet the firm faces significant headwinds from persistent operating losses and a rapidly depleting cash position.

GrowthContracting
ProfitabilityNegative
ValuationReview
TechnicalsWeak
Explore valuation models
MARKET ACTION

LSTA price & volume

Price trend, volume and key moving averages

Launch Terminal
Loading chart...
Decision Checklist4 Core Signals

What matters now

The signals most likely to change the investment case.

01

Earnings momentum

8/12 Beats

EPS beat 8 of last 12 quarters

02

Valuation risk

-102% Peers

P/E is 102% below peer median

03

Market leadership

RS 19 · Lag

Laggard (Underperforming 81% of market)

04

Weak Trend

Below 200DMA

Price < 200DMA

Next CatalystEstimated earnings · Feb 13

Market performance

Price History →

Trailing total returns as of 11/18/2026, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC).

YTD Return
LSTA-46.94%
S&P 500 (^GSPC)+7.21%
1-Year Return
LSTA-50.24%
S&P 500 (^GSPC)+10.03%
3-Year Return
LSTA-54.98%
S&P 500 (^GSPC)+55.68%
5-Year Return
LSTA-93.27%
S&P 500 (^GSPC)+52.56%

Growth & profitability

Annual revenue & EPS trend
Revenue FY25
$170K-83.0% YoY
Net income FY25
-$17M+17.0% YoY
Free cash flow FY25
-$16M+17.5% YoY
Operating margin FY25
-10711.2%-8470.3 pts YoY
ROIC (FY25)-229.7%
Avg ROIC 5Y-103.3%
ROE (TTM)-167.8%
Piotroski Score1 / 9
Financial Statements →
03

Monitor what changed

Recent results and news deserve attention only when they alter the forward view.

OPERATING RESULTS

Recent Earnings

Earnings History
EPS Beat Rate8/12 (80%)
Revenue Beat Rate0/12 (0%)
QuarterEPS (Act vs Est)Revenue (Act vs Est)
Q4 2026Latest
Nov 13, 2026
-$0.73+35.1%
vs -$1.13
—
vs $659,000
Q3 2026
Aug 6, 2026
-$0.32
vs —
—
vs —
Q2 2026
May 14, 2026
-$0.50
vs —
—
vs $94,351
Q2 2026
Mar 12, 2026
-$0.74-45.1%
vs -$0.51
$100,000+0.0%
vs $100,000
Historical baseline: 12 quarters analyzedGAAP / Adjusted
MARKET COVERAGE

Latest News

4 Stories
GlobeNewsWire·Nov 9, 2026
Marea Therapeutics, a Subsidiary of Lisata Therapeutics, Announces MAR001 Reduces Triglycerides Without Worsening Glycemic Control in Phase 2b TYDAL-TIMI 78 Trial; Results Presented as AHA 2026 Late-Breaker and Published in The New England Journal of Medicine

Part A of TYDAL-TIMI 78 Trial met all objectives, with statistically significant placebo-adjusted triglyceride reductions of 39.1%–45.5% across all three doses at Week 12 and up to 57.2% in participants with baseline triglycerides ≥300 mg/dL

GlobeNewsWire·Nov 5, 2026
Marea Therapeutics, a Subsidiary of Lisata Therapeutics, to Participate in Upcoming November Investor Conferences

SOUTH SAN FRANCISCO, Calif. and LIBERTY CORNER, N.J.

Proactive Investors·Oct 15, 2026
Lisata adds biopharma finance veteran Jeffrey Farrow to board

Lisata Therapeutics Inc (NASDAQ:LSTA, FRA:8NE) said it has appointed Jeffrey Farrow, a veteran biopharma finance executive, to its board of directors.  Farrow fills a newly created seat, expanding the board from seven to eight members.

Defense World·Oct 15, 2026
Financial Survey: Lisata Therapeutics (NASDAQ:LSTA) vs. Dyadic International (NASDAQ:DYAI)

Dyadic International (NASDAQ: DYAI - Get Free Report) and Lisata Therapeutics (NASDAQ: LSTA - Get Free Report) are both small-cap healthcare companies, but which is the better stock? We will compare the two businesses based on the strength of their valuation, earnings, analyst recommendations, institutional ownership, profitability, dividends and risk. Profitability This table compares Dyadic International and

Filtered for Lisata Therapeutics, Inc.More Headlines
04

Compare before deciding

Benchmark LSTA against direct peers instead of judging its metrics in isolation.

Peers Comparison

Key metrics vs top competitors for Lisata Therapeutics, Inc. (LSTA)

Full Screener →
CompanyPriceMarket CapP/E RatioRev Growth (1Y)Net MarginROEDiv Yield
LSTA logoLSTALisata Therapeutics, Inc.Current
$1.04$9.47M-0.56-83%-17159%-167.79%—
ADCT logoADCTADC Therapeutics S.A.
$1.35$171.71M-2.5814.85%-96.66%——
IMVT logoIMVTImmunovant, Inc.
$33.21$6.85B-13.49—-7173.52%-63.01%—
TPVG logoTPVGTriplePoint Venture Growth BDC Corp.
$3.70$150.22M6.9155.25%58.87%6.24%27.7%
CRVS logoCRVSCorvus Pharmaceuticals, Inc.
$10.17$855.2M-14.62——-34.98%—
NKTR logoNKTRNektar Therapeutics
$35.91$1.23B-6.92-43.89%-339.67%-29.31%—

Compare LSTA vs Peers

Lisata Therapeutics, Inc. (LSTA) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.

Closest Rival

vs ADCT

Most directly comparable listed peer for LSTA.

Scale Benchmark

vs IQV

Larger-name benchmark to compare LSTA against a more recognizable public peer.

Peer Set

Compare Top 5

vs ADCT, IMVT, TPVG, CRVS

05

Keep researching

Verify the primary filings, follow material updates, and answer the remaining questions.

LSTA SEC Filings & Documents

Lisata Therapeutics, Inc. (LSTA) SEC filings — annual & quarterly reports (10-K, 10-Q)

8-K Announcements

6
Material company update

Nov 9, 2026·SEC

Material company update

Aug 4, 2026·SEC

Material company update

Jul 24, 2026·SEC

10-K Annual Reports

3
FY 2026

Mar 12, 2026·SEC

FY 2025

Feb 27, 2025·SEC

FY 2024

Feb 29, 2024·SEC

10-Q Quarterly Reports

6
FY 2026

Nov 13, 2026·SEC

FY 2026

Aug 6, 2026·SEC

FY 2026

May 11, 2026·SEC

Get notified when LSTA posts new earnings or crosses analyst targets

Free. No account needed. Unsubscribe any time.

Free. Unsubscribe any time.

LSTA Frequently Asked Questions

Lisata Therapeutics, Inc. (LSTA) stock FAQ — growth, dividends, profitability & financials explained

Growth & Financials
What is Lisata Therapeutics, Inc.'s revenue?

Lisata Therapeutics, Inc. (LSTA) reported $0.1M in revenue over the trailing twelve months. Revenue was $0.2M in fiscal year 2025. That is 99% less than the $21.1M of fiscal year 1995.

How fast is Lisata Therapeutics, Inc. growing?

Lisata Therapeutics, Inc. (LSTA) revenue fell by 90.7% over the trailing twelve months, compared with the twelve months before.

Is LSTA profitable?

No. Lisata Therapeutics, Inc. (LSTA) reported a net loss of $17.2M over the trailing twelve months.

Dividend & Returns
What is LSTA's return on equity?

Lisata Therapeutics, Inc. (LSTA) had a return on equity (ROE) of -167.8% over the trailing twelve months. A negative ROE means the company lost money over the period.

What is Lisata Therapeutics, Inc.'s free cash flow?

Lisata Therapeutics, Inc. (LSTA) had negative free cash flow of $21.7M over the trailing twelve months.

What if you invested $1,000 in LSTA back in 1995?

Total return calculator · dividends reinvested · 31+ years of data

See returns →